Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252174 · ClinicalTrials.gov registry record · Phase 2
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00252174 is a Phase 2 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 2 participants.
The verdict
NCT00252174, a Phase 2 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a pilot study intended to find out if 3,4-methylenedioxymethamphetamine (MDMA) is safe and can help people with advanced stage cancer and anxiety arising from the cancer diagnosis.
Interventions
- BEHAVIORAL Psychotherapy
- DRUG Stage 1 Active Methylenedioxymethamphetamine
- DRUG Stage 1 Low dose Methylenedioxymethamphetamine
- DRUG Stage 2 Active Methylenedioxymethamphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-02 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252174
The ClinicalTrials.gov registry entry for NCT00252174 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Psychotherapy is the first listed.
NCT00252174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252174 about?
NCT00252174 is a clinical study titled "MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer". This is a pilot study intended to find out if 3,4-methylenedioxymethamphetamine (MDMA) is safe and can help people with advanced stage cancer and anxiety arising from the cancer diagnosis.
What is the current status of trial NCT00252174?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2007-02. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00252174?
The interventions under investigation include: Psychotherapy (BEHAVIORAL), Stage 1 Active Methylenedioxymethamphetamine (DRUG), Stage 1 Low dose Methylenedioxymethamphetamine (DRUG), Stage 2 Active Methylenedioxymethamphetamine (DRUG).
Who is sponsoring clinical trial NCT00252174?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.